Efficacy and Safety of Ebronucimab, a Monoclonal Antibody Against Pcsk9, in Patients With Hyperlipidemia: Result From a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study

被引：0
|
作者：
Zhen, Wang
Pei, Zhaohui
Chen, Jiyan
Zhang, Guogang
Li, Dongye
Xia, Yu
Li, Baiyong
Wang, Max
Ni, Xiang
Wang, Guoqin
Ge, Junbo
机构：
来源：
CIRCULATION | 2022年 / 146卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A10451
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Efficacy and safety of etrasimod in alopecia areata: A multicentre, randomized, double-blind, placebo-controlled, Phase 2 study
    King, B.
    Mesinkovska, N.
    Senna, M.
    Luo, X.
    Minkiewicz, J.
    Selfridge, A.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2025,
  • [22] Efficacy and Safety of AMG 853 in Asthma: Results of a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
    Busse, W. W.
    Wenzel, S. E.
    Meltzer, E. O.
    Kerwin, E. M.
    Liu, M. C.
    Zhang, N.
    Chon, Y.
    Lin, J.
    Lin, S.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2012, 129 (02) : AB202 - AB202
  • [23] Efficacy and safety of guselkumab, an anti-IL23 Monoclonal antibody, in patients with active psoriatic arthritis: A phase 2a, randomized, double-blind, placebo-controlled study
    Gottlieb, Alice
    Deodhar, Atul
    Boehncke, Wolf-Henning
    Dong, Bin
    Wang, Yuhua
    Barchuk, William
    Hsia, Elizabeth
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB111 - AB111
  • [24] Safety and efficacy of ataluren in nmDMD patients from Study 041, a phase 3, randomized, double-blind, placebo-controlled trial
    McDonald, C.
    Wu, S.
    Gulati, S.
    Komaki, H.
    Ruiz-Garcia, M.
    Kostera-Pruszczyk, A.
    Vlodavets, D.
    Chae, J.
    Jong, Y.
    Karachunski, P.
    Statland, J.
    Lorentzos, M.
    Penematsa, V
    Chou, C.
    Lin, M.
    Werner, C.
    Trifillis, P.
    Gordon, G.
    Klein, M.
    NEUROMUSCULAR DISORDERS, 2022, 32
  • [25] Safety and Efficacy of Ataluren in nmDMD Patients from Study 041, a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial
    McDonald, Craig M.
    Wu, Shiwen
    Gulati, Sheffali
    Komaki, Hirofumi
    Escobar, Rosa E.
    Kostera-Pruszczyk, Anna
    Vlodavets, Dmitry
    Chae, Jong-Hee
    Jong, Yuh-Jyh
    Karachunski, Peter
    Statland, Jeffrey
    Lorentzos, Michelle
    Penematsa, Vinay
    Chou, Connie
    Lin, Min
    Werner, Christian
    Trifillis, Panayiota
    Gordon, Gregory
    Koladicz, Karyn
    Mastrandrea, Nicholas
    Klein, Matthew
    NEUROLOGY, 2023, 100 (17)
  • [26] A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study of Tildrakizumab Efficacy and Safety in Patients With Active Ankylosing Spondylitis
    Peters, Eric
    Chou, Richard C.
    Rozzo, Stephen J.
    Yao, Siu-Long
    Fructuoso, Ferran Jose Garcia
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2023, 29 (05) : 223 - 229
  • [27] Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: Results from a randomized, double-blind, phase-2, placebo-controlled study
    Hershberger, Ellie
    Sloan, Susan
    Narayan, Kristin
    Hay, Catherine A.
    Smith, Patrick
    Engler, Rank
    Jeeninga, Rienk
    Smits, Saskia
    Trevejo, Jose
    Shriver, Zach
    Oldach, David
    EBIOMEDICINE, 2019, 40 : 574 - 582
  • [28] CETACAINE EFFICACY - A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY
    LACHTER, J
    JACOBS, R
    LAVY, A
    SUISSA, A
    WEISLER, A
    EIDELMAN, S
    GASTROENTEROLOGY, 1988, 94 (05) : A245 - A245
  • [29] Efficacy and safety of oxycodone DETERx: results of a randomized, double-blind, placebo-controlled phase III study
    Kopecky, E.
    O'Connor, M.
    Varanasi, R.
    Saim, S.
    Fleming, A.
    JOURNAL OF PAIN, 2015, 16 (04): : S87 - S87
  • [30] Efficacy and Safety of Novel Aspirin Formulations: A Randomized, Double-Blind, Placebo-Controlled Study
    Mollace, Rocco
    Gliozzi, Micaela
    Macri, Roberta
    Tavernese, Annamaria
    Musolino, Vincenzo
    Carresi, Cristina
    Maiuolo, Jessica
    Muscoli, Carolina
    Tomino, Carlo
    Rosano, Giuseppe Maria
    Fini, Massimo
    Volterrani, Maurizio
    Silvestrini, Bruno
    Mollace, Vincenzo
    PHARMACEUTICS, 2022, 14 (01)
12345